Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMPRSS15 | P98073 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 1/20 | 0.42 |
| ▸ | GART | P22102 | 5/20 | 0.41 |
| ▸ | FOLR2 | P14207 | 1/20 | 0.41 |
| ▸ | FOLR1 | P15328 | 1/20 | 0.41 |
| ▸ | SLC19A1 | P41440 | 1/20 | 0.41 |
| ▸ | SLC46A1 | Q96NT5 | 1/20 | 0.41 |
| ▸ | FOLH1 | Q04609 | 5/20 | 0.41 |
| ▸ | DHFR | P00374 | 3/20 | 0.40 |
| ▸ | MMP3 | P08254 | 1/20 | 0.39 |
| ▸ | ATIC | P31939 | 2/20 | 0.39 |
| ▸ | SHMT1 | P34896 | 2/20 | 0.39 |
| ▸ | SHMT2 | P34897 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15948343 | 0.95 | PPARA (0.44) | TMPRSS15PPARAGARTFOLR2FOLR1 | |
| SCHEMBL14821760 | 0.92 | CA2 (0.40) | TMPRSS15PPARAGARTFOLR2FOLR1 | |
| SCHEMBL14821521 | 0.92 | TMPRSS15 (0.43) | TMPRSS15PPARAGARTFOLR2FOLR1 | |
| SCHEMBL15946453 | 0.91 | TMPRSS15 (0.44) | TMPRSS15PPARAMMP3 | |
| SCHEMBL14821498 | 0.91 | TMPRSS15 (0.44) | TMPRSS15GARTFOLR2FOLR1SLC19A1 | |
| SCHEMBL14821755 | 0.87 | ITGB3 (0.41) | TMPRSS15PPARAGARTFOLR2FOLR1 | |
| SCHEMBL14821496 | 0.87 | TMPRSS15 (0.44) | TMPRSS15PPARAMMP3CA1CA2 | |
| SCHEMBL14821748 | 0.87 | PPARA (0.44) | TMPRSS15PPARAGARTFOLR2FOLR1 | |
| SCHEMBL15948350 | 0.85 | TMPRSS15 (0.43) | TMPRSS15PPARA | |
| SCHEMBL14821753 | 0.84 | TMPRSS15 (0.42) | TMPRSS15FOLH1DHFRCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2758367-B1 | NOVEL ISOCYANATE AND ISOTHIOCYANATE COMPOUNDS FOR CANCER TREATMENT | DoubleHill GmbH (DE) | 2015-11-18 | — | — | EP | disclosed |
| US-8987316-B2 | Isocyanate and isothiocyanate compounds for cancer treatment | DoubleHill GmbH (DE) | 2015-03-24 | — | — | US | disclosed |
| US-8987316-B2 | Isocyanate and isothiocyanate compounds for cancer treatment | DoubleHill GmbH (DE) | 2015-03-24 | — | — | US | disclosed |
| US-20140228419-A1 | Novel Isocyanate And Isothiocyanate Compounds For Cancer Treatment | DoubleHill GmbH (DE) | 2014-08-14 | — | — | US | disclosed |
| US-20140228419-A1 | Novel Isocyanate And Isothiocyanate Compounds For Cancer Treatment | DoubleHill GmbH (DE) | 2014-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140228419-A1 | Novel Isocyanate And Isothiocyanate Compounds For Cancer Treatment | IDH3A, IDH3B, IDH2 | TMPRSS15 1400/4885PPARA 3425/4885GART 3553/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.